Get inspired
PUBLICATIONS
Since the center inauguration, participants in the center have consistently published their research findings and conclusions in international renowned journals. The ctDNA Center has international collaborations with both academic and commercial partners, actively participation in various international networks and societies focused on ctDNA. We prioritize sharing our findings and results both publicly and within the research community,
Find the scientific publications below.
Popular science articles
Find articles in news media here
75. ctDNA-based minimal residual disease detection in lung cancer patients treated with curative intended chemoradiotherapy using a clinically transferable approach
Lærke Rosenlund Nielsen, Simone Stensgaard, Peter Meldgaard, Boe Sandahl Sørensen
(2024, February). Cancer Treatment and Research Communications, 39:100802. DOI: 10.1016/j.ctarc.2024.100802. PMID: 38428066
74. KIDNEY-PAGER: analysis of circulating tumor DNA as a biomarker in renal cancer - an observational trial. Study protocol
Laura Iisager, Johanne Ahrenfeldt, Anna Krarup Keller, Tommy Kjærgaard Nielsen, Niels Fristrup, Iben Lyskjær
(2024, February). Acta Oncologica, 63: 51-55. DOI: 10.2340/1651-226X.2024.25581. PMID: 38391290
73. Extraction of Cell-Free DNA: Evaluation of Efficiency, Quantity, and Quality
Simone K. Terp, Inge S. Pedersen, Malene P. Stoico
(2024, February). The Journal of Molecular Diagnostics, S1525-1578(24)00014-X. DOI: 10.1016/j.moldx.2024.01.008. PMID: 38336350
72. Methylated Cell-Free Tumor DNA in Sputum as a Tool for Diagnosing Lung Cancer - A Systematic Review and Meta-Analysis
Sara Witting Christensen Wen, Morten Borg, Signe Timm, Torben Frøstrup Hansen, Anders Jakobsen, Ole Hilberg, Rikke Fredslund Andersen
(2024). Cancers, 16(3): 506. DOI: 10.3390/cancers16030506. PMID: 38339257
71. Assessment of circulating biomarkers for detection of lung cancer in a high-risk cohort
Morten Borg, Line Nederby, Sara Witting Christensen Wen, Torben Frøstrup Hansen, Anders Jakobsen, Rikke Fredslund Andersen, Ulla Møller Weinreich, Ole Hilberg
(2023). Cancer Biomarkers, 36(1):63-69. DOI: 10.3233/CBM-210543. PMID: 36404535
70. Unraveling the potential clinical utility of circulating tumor DNA detection in colorectal cancer - evaluation in a nationwide Danish cohort
T.V. Henriksen, C. Demuth, A. Frydendahl, J. Nors, M. Nesic, M.H. Rasmussen, T. Reinert, O.H. Larsen, C.Jaensch, U.S. Løve, P.V. Andersen, T. Kolbro, O. Thorlacius-Ussing, A. Monti, M. Gögenur, J. Kildsig, P. Bondeven, N.H. Schlesinger, L.H. Iversen, K.A. Gotschalck, C.L. Andersen
(2023, November). Annals of Oncology. DOI: 10.1016/j.annonc.2023.11.009. PMID: 37992872
69. Circulating DNA and frequency of colorectal cancer brain metastases in a presumed high-risk group
Louise Bach Callesen, Anders Kindberg Boysen, Rikke Fredslund Andersen, Rikke Beese Dalby, Karen-Lise Garm Spindler
(2023, October). Scientific Reports,, 13(1):18574. DOI: 10.1038/s41598-023-45939-x. PMID: 37903871
68. Liquid Biopsies with Circulating Plasma HPV-DNA Measurements - A Clinically Applicable Surveillance Tool for Patients with HPV-Positive Oropharyngeal Cancer
Kathrine K. Jakobsen, Simone K. Bendtsen, Niels Pallisgaard, Jeppe Friborg, Giedrius Lekaitis, Christian Grønhøj, Christian von Buchwald
(2023, October). Clinical Cancer Research, 29(19):3914-3923. DOI: 10.1158/1078-0432.CCR-23-1064. PMID: 37477909
67. Circulating tumor DNA analysis in advanced urothelial carcinoma: Insights from biological analysis and extended clinical follow-up
Sia V. Lindskrog, Karin Birkenkamp-Demtröder, Iver Nordentoft, George Laliotis, Philippe Lamy, Emil Christensen, Derrick Renner, Tine G. Andreasen, Naja Lange, Shruti Sharma, Adam C. ElNaggar, Minetta C. Liu, Himanshu Sethi, Alexey Aleshin, Mads Agerbæk, Jørgen B. Jensen, Lars Dyrskjøt
(2023, October). Clinical Cancer Research. DOI: 110.1158/1078-0432.CCR-23-1860. PMID: 37782315
66. Field Cancerization is Associated with Tumor Development, T-cell Exhaustion, and Clinical Outcomes in Bladder Cancer
Trine Strandgaard, Iver Nordentoft, Karin Birkenkamp-Demtröder, Liina Salminen, Frederik Prip, Julie Rasmussen, Tine Ginnerup Andreasen, Sia Viborg Lindskrog, Emil Christensen, Philippe Lamy, Michael Knudsen, Torben Steiniche, Jørgen Bjerggaard Jensen, Lars Dyrskjøt
(2023, September). European Urology, S0302-2838(23)03014-2. DOI: 10.1016/j.eururo.2023.07.014. PMID: 37718188
65. Cell-free DNA approaches for cancer early detection and interception
Jamie E. Medina, Nicholas C. Dracopoli, Peter B. Bach, Anna Lau, Robert B. Scharpf, Gerrit A. Meijer, Claus Lindbjerg Andersen, Victor E. Velculescu
(2023, September). Journal of Immunotheraoy of Cancer, 11(9):e006013. DOI: 10.1136/jitc-2022-006013. PMID: 37696619
64. ctDNA-guided adjuvant treatment after radical-intent treatment of metastatic spread from colorectal cancer-the first interim results from the OPTIMISE study
Louise Bach Callesen, Torben Frøstrup Hansen, Rikke Fredslund Andersen, Niels Pallisgaard, Stine Kramer, Sven Schlander, Søren Rafael Rafaelsen, Anders Kindberg Boysen, Lars Henrik Jensen, Anders Jakobsen, Karen-Lise Garm Spindler
(2023, September). Acta Oncologica, 22; 1-7. DOI: 10.1080/0284186X.2023.2259083 PMID: 37738268
63. Methylated Circulating Tumor DNA in Blood as a Tool for Diagnosing Lung Cancer: A Systematic Review and Meta-Analysis
Morten Borg, Sara Witting Christensen Wen, Rikke Fredslund Andersen, Signe Timm, Torben Frøstrup Hansen, Ole Hilberg
(2023, August). Cancers (Basel), 15(15);3959. DOI: 10.3390/cancers15153959. PMID: 37568774
62. The Importance of Feasibility Assessment in the Design of ctDNA Guided Trials - Results from the OPTIPAL II Study
Luise Bach Callesen, Anders Kindberg Boysen, Christina Søs Audur Andersen, Niels Pallisgaard, Karen-Lise Garm Spindler
(2023, August). Clinical Colorectal Cancer, S1533-0028(23)00064-5. DOI: 10.1016/j.clcc.2023.07.005. PMID: 37586928
61. NK cell activity and methylated HOXA9 ctDNA as prognostic biomarkers in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitors
Sara Witting Christensen Wen, Line Nederby, Rikke Fredslund Andersen, Torben Scjødt Hansen, Christa Haugaard Nyhus, Ole Hilberg, Anders Jakobsen, Torben Frøstrup Hansen
(2023, July). British Journal of Cancer, 129(1):135-142. DOI: 10.1038/s41416-023-02285-z. PMID: 37137997
60. IBCN Seminar Series 2021: Circulating tumor DNA in bladder cancer
Emil Christensen, Alexander W Wyatt, Matthew D Galsky, Petros Grivas, Roland Seiler, Roman Nawroth Peter J Goebell, Bernd J Schmitz-Drager, Stephen B Williams, Peter C Black, Ashish M Kamat, Tilman Todenhöfer, Lars Dyrskjøt
(2023, July). Urologic Oncology, 41(7). Pages 318-322. DOI: 10.1016/j.urolonc.2022.11.008. PMID: 36437155
59. 25 years International Bladder Cancer Network (IBCN): The past, the present, and the future25 years International Bladder Cancer Network (IBCN): The past, the present, and the future
Lars Dyrskjøt, Antonia Vlahou, Peter C Black, Michael Droller, H Barton Grossmann, Peter J Goebell, Ashish M Kamat, Roman Nawroth, Roland Seiler, Tilman Todenhöfer, Stephen B Williams, Bernd J Schemitz-Dräger
(2023, July). Urologic Onvology, 41(7). Pages 302-306. DOI: 10.1016/j.urolonc.2022.10.031. PMID: 36437158
58. NGS-Based Tumor-Informed Analysis of Circulating Tumor DNA
Iver Nordentoft, Karin Birkenkamp-Demtröder, Lars Dyrskjøt
(2023, July). Part of the 'Methods in Molecular Biology' book series (MIMB, volume 2684). DOI: 10.1007/978-1-0716-3291-8_11. PMID: 37410235
57. Circulating tumor DNA as a Predictive and Prognostic Biomarker in the Perioperative Treatment of Muscle-invasive Bladder Cancer: A systematic Review
Emanuele Crupi, Tiago Costa de Padua, Laura Marandino, Daniele Raggi, Lars Dyrskjøt, Philippe E Spiess, Guru P Sonpavde, Ashish M Kamat, Andrea Necchi
(2023, June). European Urology Oncology, S2588-9311(23)00111-6. DOI: 10.1016/j.euo.2023.05.012. PMID: 37330413
56. Phase II trial of delta-tocotrienol in neoadjuvant breast cancer with evaluation of treatment response using ctDNA
Ina Mathilde Kjær, Søren Kahns, Signe Timm, Rikke Fredslund Andersen, Jonna Skov Madsen, Erik Hugger Jakobsen, Thomasz Piotr Tabor, Anders Jakobsen, Troels Bechmann
(2023, May). Scientific Reports, 13(1):8419. DOI: 10.1038/s41598-023-35362-7. PMID: 37225860
55. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA
Christopher Abbosh, Alexander M. Frankell, Thomas Harrison, Judit Kisistok, Aaron Garnett, Laura Johnson, Selvaraju veeriah, Mike Moreau, Adrian Chesh, Tafadzwa L. Chaunzwa, Jakob Weiss, Morgan R. Schroeder, Sophia Ward, Kristiana Grigoriadis, Aamir Shahpurwalla, Kevin Litchfield, Clare Puttick, Dhruva Biswas, Takahiro Karasaki, James R. M. Black, Carlos Martínes-Ruiz, Maise Al Bakir, Oriol Pich, Thomas B. K. Watkins, Emilia L. Lim, Ariana Huebner, David A. Moore, Nadia Godin-Heymann, Anne L'Hernault, Hannah Bye, Aaron Odell, Paula Roberts, Fabio Gomes, Akshay J. Patel, Elizabeth Manzano, Crispin T. Hiley, Nicolas Carey, Joan riley, Daniel E. Cook, Darren Hodgson, Daniel Stetson, J. Carl Barrett, Roderik M. Kortlever, Gerard I. Evan, Allan Hacksshaw, Robert D. Daber, Jacqui A. Shaw, Hugo J. W. L. Aerts, Abel Licon, Josh Stahl, Mariam Jamal-Hanjani, TRACERx Consortium, Nicolai J. Birkbak, Nicholas McGranahan, Charles Swanton
(2023, April). Nature 616. Pages 553-562. Doi: 10.1038/s41586-023-05776-4. PMID: 37055640
54. Circulating tumor DNA: Response Evaluation Criteria in Solid Tumors - can we RECIST? Focus on colorectal cancer
Karen-Lise Garm Spindler, Anders Jacobsen
(2023, April). Therapeutic Advances in Medical Oncology, vol 15. Pages 1-11. Doi: 10.1177/17588359231171580
53. DREAMS: deep read-level error model for sequencing data applied to low-frequency variant caling and circualting tumor DNA detection
Mikkel H. Christensen, Simon O. Due, Mads H. Rasmussen, Amanda Frydendahl, Iben Lyskjær, Christina Demuth, Jesper Nors, Kåre A. Gotschalck, Lene H. Iversen, Claus L. Andersen, Jakob Skou Pedersen
(2023, April). Genome Biology 24, 99. Doi: 10.1186/s13059-023-02920-1
52. Early diagnosis of ovarian cancer based on methylation profiles in peripheral blood cell-free DNA: a systematic review
Simone Karlsson Terp, Malene Pontoppidan Stoico, Karen Dybkær, Inge Søkilde Pedersen
(2023, February). Clin Epigenet 15, 24 Doi: 10.1186/s13148-023-01440-w. PMID: 36788585
51. Prognostic Value of Low-Pass Whole Genome Sequencing of Circulating Tumor DNA in Metastatic Castration-Resistant Prostate Cancer
Maibritt Nørgaard, Marianne T Bjerre, Jacob Fredsøe, Søren Vang, Jørgen B Jensen, Bram De Laere, Henrik Grönberg, Michael Borre, Johan Lindberg, Karina D Sørensen
(2023, February). Clinical Chemistry hvac224. Doi: 10.1093/clinchem/hvac224. PMID: 36762756
50. Cell-free urine-and plasma DNA mutational analysis predicts neoadjuvant chemotherapy response and outcome in patients with muscle invasive bladder cancer
Emil Christensen, Iver Nordentoft, Karin Birkenhamp-Demtröder, Sara K. Elbæk, Sia V. Lindskrog, Ann Taber, Tine G. Andreasen, Trine Strandgaard, Michael Knudsen, Philippe Lamy, Mads Agerbæk, Jørgen B. Jensen, Lars Dyrskjøt
(2023, February). Clinical Cancer Research, 13;CCR-22-3250. doi: 10.1158/1078-0432.CCR-22-3250. PMID: 36780195
49. ctDNA-Response evaluation criteria in solid tumors - a new measure in medical oncology
Anders K. M. Jakobsen, Karen-Lise Garm Spindler
(2023, February). European Journal of Cancer, 180. Pages 180-183. doi: 10.1016/j.ejca.2022.11.039. PMID: 36610263
48. Impact of Whole Genome Doubling on Dettection of Circulating Tumor DNA in Colorectal Cancer
Jonas Kabel, Tenna Vesterman Henriksen, Christina Demuth, Amanda Frydendahl, Mads Heilskov Rasmussen, Jesper Nors, Nicolai J. Birkbak, Anders Husted Madsen, Uffe S. Løve, Per Vadgaard Andersen, Thomas Kolbro, Alessio Monti, Ole Thorlacius-Ussing, Mikail Gögenur, Jeppe Kildsig, Nis Hallundbæk Schlesinger, Peter Bondeven, Lene Hjerrild Iversen, Kåre Andersson Gotschalck, Claus Lindbjerg Andersen
(2023, February). Cancers, 15(4), 1136. doi: 10.3390/cancers15041136. PMID: 36831479
47. Elevated T-cell Exhaustion and Urinary Tumor DNA Levels Are Associated with Bacillus Calmette-Guérin Failure in Patients with Non–muscle-invasive Bladder Cancer
Trine Strandgaard; Sia Viborg Lindskrog; Iver Nordentoft; Emil Christensen; Karin Birkenkamp-Dermtröder; Trine Ginnerup Andreasen; Philippe Lamy; Asbjørn Kjær; Daniel Ranti; Yuan-Sho Wang; Christine Bieber; Frederik Prip; Julie Rasmussen; Torben Steiniche; Nicolai Birkbak; John Sfakianos; Amir Horowitz; Jørgen Bjerggaard Jensen; Lars Dyrskjøt
(2022, December). European Urology, 82(6). Pages 646-656. Doi: 10.1016/j.eururo.2022.09.008. PMID: 36210217
46. Circulating DNA in patients undergoing loco-regional treatment of colorectal cancer metastases: a systematic review and meta-analysis
Callesen LB, Takacova T, Hamfjord J, et al.
(2022, November). Therapeutic Advances in Medical Oncology, 14. doi:10.1177/17588359221133171. PMID: 36339929
45. Pre-and Postoperative Circulating Tumour DNA in Patients With Gastrointestinal Stromal Tumour - A Methodological Assessment Study
Brinch CM, Aggerholm-Pedersen N, Poulsen TS, Skovrider-Ruminski W, DE Heer P, Penninga L, Krarup-Hansen A, Hogdall E.
(2022, November). Anticancer Res., 42(11):5527-5537. Doi: 10.21873/anticanres.16022. PMID: 36288871
44. Circulating tumor DNA monitoring reveals molecular progression before radiologic progression in a real-life cohort of advanced Non-Small Cell Lung Cancer patients
Frank M.S., Andersen C.S.A., Ahlborn L.B., Pallisgaard N., Bodtger U., Gehl J.
(2022, September). Cancer Research Communications. doi: 10.1158/2767-9764.CRC-22-0258
43. Circulating cell-free DNA as predictor of pathological complete response in locally advanced rectal cancer patients undergoing preoperative chemoradiotherapy
Truelsen CG, Kronborg CS, Sørensen BS, Callesen LB, Spindler KG.
(2022, September). Clinical and Translational Radiation Oncology, 36. Pages 9-15. doi: 10.1016/j.ctro.2022.06.002. PMID: 35733829
42. OPTIMISE: Optimisation of treatment selection and follow-up in oligometastatic colorectal cancer - a ctDNA-guided phase II randomised approach. Study protocol
Callesen LB, Hansen TF, Andersen RF, Pallisgaard N, Kramer S, Schlander S, Rafaelsen SR, Boysen AK, Jensen LH, Jakobsen A, Spindler KG.
(2022, September). Acta Oncoloca, 12:1-5. doi: 10.1080/0284186X.2022.2116728. PMID: 36094310
41. ctDNA-Guided Adjuvant Chemotherapy for Colorectal Cancer - Ready for Prime Time
Andersen, CL; Heitzer, E.
(2022, September). Cancer Cell, 40(9). Pages 911-913. doi: 10.1016/j.ccell.2022.08.017. PMID: 36055230
40. Circulating tumour DNA and its clinical utility in predicting treatment response or survival in patients with metastatic colorectal cancer: a systematic review and meta-analysis
Callesen LB, Hamfjord J, Boysen AK, Pallisgaard N, Guren TK, Kure EH, Spindler KG.
(2022, August). British Journal of Cancer, 127(3). Pages 500-513. doi: 10.1038/s41416-022-01816-4. PMID: 35440666
39. ctDNA for Risk of Recurrence Assessment in Patients Treated with Neoadjuvant Treatment: A Systematic Review and Meta-analysis
Gögenur M, Hadi NA, Qvortrup C, Andersen CL, Gögenur I.
(2022, August). Annals of Surgical Oncology. doi: 10.1245/s10434-022-12366-7. PMID: 35933546
38. Comparing Single-target and Multitarget Approaches for Postoperative Tumour DNA Detection in Stage II-III Colorectal Cancer Patients
Henriksen, T. V., Reinert, T., Rasmussen, M. H., Demuth, C., Løve, U. S., Madsen, A. H., Gotschalck, K. A., Iversen, L. H., & Andersen, C. L.
(2022, July). Molecular Oncology. doi: 10.1002/1878-0261.13294. PMID: 35895438
37. Unsupervised Detection of Fragment Length Signatures of Circulating Tumor DINA using non-negative Metrix Factorization
Reanud, G., Nørgaard, M., Lindberg, J., Grönberg, H., De Laere, B., Jensen, J. B., Borre, M., Andersen, C. L., Sørensen, K. D., Maretty, L. & Besenbacher, S.
(2022, July). Elife, 11, e71569. doi: 10.7554/eLife.71569. PMID: 35894300
36. The Diagnostic Value of Circulating Cell-Free HPV DNA in Plasma from Cervical Cancer Patients
Bønløkke S, Stougaard M, Sorensen BS, Booth BB, Høgdall E, Nyvang GB, Lindegaard JC, Blaakær J, Bertelsen J, Fuglsang K, Strube ML, Lenz S, Steiniche T.
(2022, July). Cells, 11(14):2170. Doi: 10.3390/cells11142170. PMID: 35883612
35. Reporting on circulating tumor DNA monitoring in metastatic cancer—From clinical validity to clinical utility
Thomsen, C.B, Juul, A.D., Lefèvre, A.C., Truelsen, C.G., Dizdarevic, E., Ryssel, H., Kjær, I.M., Wind, K.L., Callesen, L.B., Larsen, L.F., Frank, M.S., Andersen, R.F., Spindler, K.G., Jakobsen, A.
(2022, June). Cancer, 128(11). Pages 2052-2057. doi: 10.1002/cncr.34168. PMID: 35302663
34. Error characterization and statistical modeling improves Circulating Tumor DNA detection by droplet digital PCR
Henriksen, T. V., Drue, S. O., Frydendahl, A., Demuth, C., Rasmussen, M. H., Reinert, T., Pedersen, J. S. & Andersen, C. L
(2022, May). Clinical Chemistry, 68(5). Pages 657-667. doi: 10.1093/clinchem/hvab274. PMID: 35030248
33. Circulating Tumor DNA for Prognosis and Postoperative Management after Curative-intent Resection of Colorectal Liver Metastases
Reinert, T., Petersen, L. M. S., Henriksen, T. V., Larsen, M. Ø., Rasmussen, M. H., Johansen, A. F. B., Øgaard, N., Knudsen, M., Nordentoft, I., Vang, S., Krag, S. R. P., Knudsen, A. R., Mortensen, F. V. & Andersen, C. L.
(2022, May). International Journal of Cancer, 150(9). Pages 1537-1548. doi: 10.1002/ijc.33924. PMID: 34994972
32. Cell Free Methylated Tumor DNA in Bronchial Lavage as an Additional Tool for Diagnosing Lung Cancer-A Systematic Review
Wen SWC, Wen J, Hansen TF, Jakobsen A, Hilberg O.
(2022, April). Cancers (Basel), 14(9):2254. Doi: 10.3390/cancers14092254. PMID: 35565384
31. The Prognostic Importance of ctDNA in Rectal Cancer: A Critical Reappraisal
Dizdarevic E, Hansen TF, Jakobsen A.
(2022, April). Cancers (Basel), 14(9):2252. Doi: 10.3390/cancers14092252. PMID: 35565381
30. Total cell-free DNA measurement in metastatic colorectal cancer with a fast and easy direct fluorescent assay
Callesen LB, Sørensen BS, Pallisgaard N, Laugesen IG, Boysen AK, Spindler KG.
(2022, March). Molecular and Clinical Oncology, 16(3). Pages 64. doi: 10.3892/mco.2022.2497. PMID: 35154704
29. Tumor-agnostic circulating tumor DNA analysis for improved recurrence surveillance after resection of colorectal liver metastases: a prospective cohort study
Øgaard N., Reinert T., Henriksen T.V., Frydendahl A., Aagaard E., Ørntoft MB. W., Larsen M.Ø., Knudsen A.R., Mortensen F.V., Andersen C.L.
(2022, March). European Journal of Cancer, 163. Pages 163-176. doi: 10.1016/j.ejca.2021.12.026. PMID: 35074652
28. Personalized circulating tumor DNA in patients with hepatocellular carcinoma: a pilot study
Pommergaard HC, Yde CW, Ahlborn LB, Andersen CL, Henriksen TV, Hasselby JP, Rostved AA, Sørensen CL, Rohrberg KS, Nielsen FC, Rasmussen A.
(2022, February). Molecular Biology Reports, 49(2). Pages 1609-1616. doi: 10.1007/s11033-021-06962-1. PMID: 34811635
27. Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of adjuvant therapy efficacy and clinical behavior of recurrences
Tenna Vesterman Henriksen, Noelia Tarazona, Amanda Frydendahl, Thomas Reinert, Francisco Gimeno-Valiente, Juan Antonio Carbonell-Asins, Shruti Sharma, Derrick Renner, Dina Hafez, Desamparados Roda, Marisol Huerta, Susana Roselló, Anders Husted Madsen, Uffe S. Løve, Per Vadgaard Andersen, Ole Thorlacius-Ussing, Lene Hjerrild Iversen, Kåre Andersson Gotschalck, Himanshu Sethi, Alexey Aleshin, Andres Cervantes and Claus Lindbjerg Andersen
(2022, February). Clinical Cancer Research, 28(3). Pages 507-517. doi: 10.1158/1078-0432.CCR-21-2404. PMID: 34625408
26. Validation of SFRP1 Promoter Hypermethylation in Plasma as a Prognostic Marker for Survival and Gemcitabine Effectiveness in Patients with Stage IV Pancreatic Adenocarcinoma
Stubbe, B.E.; Henriksen, S.D.; Madsen, P.H.; Larsen, A.C.; Krarup, H.B.; Pedersen, I.S.; Johansen, M.N.; Thorlacius-Ussing, O.
(2021, November). Cancers, 13(22). Pages 5717. doi: 10.3390/cancers13225717. PMID: 34830873
25. Analysis of HOXA9 methylated ctDNA in ovarian cancer using sense-antisense measurement
Faaborg L, Fredslund Andersen R, Waldstrøm M, Høgdall E, Høgdall C, Adimi P, Jakobsen A, Dahl Steffensen K.
(2021, November). Clin Chim Acta., 522:152-157. Doi: 10.1016/j.cca.2021.08.020. Epub 2021 Aug 19. PMID: 34419462
24. Investigation of circulating DNA integrity after blood collection
Oriane C., Veyhe S.R., Hansen M.H., Titlestad K., and Nyvold C.G.
(2021, October). BioTechniques, 71(5). Pages 550-555. doi: 10.2144/btn-2020-0167. PMID: 34645292
23. Detection and characterization of lung cancer using cell-free DNA fragmentomes
Mathios D, Johansen JS, Cristiano S, Medina JE, Phallen J, Larsen KR, Bruhm DC, Niknafs N, Ferreira L, Adleff V, Chiao JY, Leal A, Noe M, White JR, Arun AS, Hruban C, Annapragada AV, Jensen SØ, Ørntoft MW, Madsen AH, Carvalho B, de Wit M, Carey J, Dracopoli NC, Maddala T, Fang KC, Hartman AR, Forde PM, Anagnostou V, Brahmer JR, Fijneman RJA, Nielsen HJ, Meijer GA, Andersen CL, Mellemgaard A, Bojesen SE, Scharpf RB, Velculescu VE.
(2021, August). Nat Commun., 12(1):5060. Doi: 10.1038/s41467-021-24994-w. PMID: 34417454
22. Validating Methylated HOXA9 in Bronchial Lavage as a Diagnostic Tool in Patients Suspected of Lung Cancer
Wen SWC, Andersen RF, Rasmussen K, Thomsen CB, Hansen TF, Nederby L, Hager H, Jakobsen A, Hilberg O.
(2021, August). Cancers (Basel), 13(16):4223. Doi: 10.3390/cancers13164223. PMID: 34439376
21. A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies
Jensen SG, Epistolio S, Madsen CL, Kyneb MH, Riva A, Paganotti A, Barizzi J, Petersen RK, Børgesen M, Molinari F, Boldorini R, Lorenzen J, Sørensen E, Christensen UB, Høgdall E, Frattini M.
(2021, June). PLoS One, 16(6):e0253687. Doi: 10.1371/journal.pone.0253687. eCollection 2021. PMID: 34166445
20. Cell-free DNA promoter hypermethylation as a diagnostic marker for pancreatic ductal adenocarcinoma - An external validation study
Henriksen SD, Stubbe BE, Madsen PH, Johansen JS, Jensen BV, Hansen CP, Johansen MN,
Pedersen IS, Krarup H, Thorlacius-Ussing O.
(2021, May). Pancreatology 8:S1424-3903(21)00154-X. Doi: 10.1016/j.pan.2021.05.003. Online
ahead of print. PMID: 33994313
19. The Clinical Value of Measuring Circulating HPV DNA during Chemo-Radiotherapy in Squamous Cell Carcinoma of the Anus
Lefèvre AC, Pallisgaard N, Kronborg C, Wind KL, Krag SRP, Spindler KG.
(2021, May). Cancers,13(10). Pages 2451. doi: 10.3390/cancers13102451. PMID: 34070045
18. Cell-Free DNA Methylation as Blood-Based Biomarkers for Pancreatic Adenocarcinoma-A Literature Update
Henriksen SD, Thorlacius-Ussing O.
(2021, April). Epigenomes, 9;5(2):8. Doi: 10.3390/epigenomes5020008. PMID: 34968295
17. Early ctDNA response to chemotherapy. A potential surrogate marker for overall survival
Jakobsen A, Andersen RF, Hansen TF, Jensen LH, Faaborg L, Steffensen KD, Thomsen CB, Wen SWC.
(2021, April). European Journal of Cancer, 149. Pages 128-133. doi: 10.1016/j.ejca.2021.03.006. PMID: 33857886
16. Complete pathological and serological response to immunotherapy in a patient with MMR-deficient early rectal cancer
Tarpgaard LS, Andersen PV, Øgaard N, Demuth C, Andersen CL, Pfeiffer P.
(2021, March). Annals of Oncololy, 32(6). Pages 805-806. doi: 10.1016/j.annonc.2021.03.001. PMID: 33727198
15. The prognostic impact of circulating homeobox A9 methylated DNA in advanced non-small cell lung cancer
Wen SWC, Andersen RF, Hansen TF, Nyhus CH, Hager H, Hilberg O, Jakobsen A.
(2021, February). Translational Lung Cancer Reserch, 10(2). Pages 855-865. doi: 10.21037/tlcr-20-826. PMID: 33718027
14. Quantifying sequencing error and effective sequencing depth of liquid biopsy NGS with UMI error correction
Frank, M.S., Fuß, J., Steiert, T.A., Streleckiene, G., Gehl, J., Forster, M.
(2021, January). BioTechniques, 70(4). doi: 10.2144/btn-2020-0124. PMID: 33512245
13. Evaluation of a panel of tumor-specific differentially-methylated DNA regions in IRF4, IKZF1 and BCAT1 for blood-based detection of colorectal cancer
Young GP, Symonds EL, Nielsen HJ, Ferm L, Christensen IJ, Dekker E, van der Vlugt M, Mallant-Hent RC, Boulter N, Yu B, Chan M, Tevz G, LaPointe LC, Pedersen SK.
(2021, January). Clin Epigenetics, 13(1):14. Doi: 10.1186/s13148-020-00999-y. PMID: 33478584
12. Comparison of Mutated KRAS and Methylated HOXA9 Tumor-Specific DNA in Advanced Lung Adenocarcinoma
Wen SWC, Andersen RF, Petersen LMS, Hager H, Hilberg O, Jakobsen A, Hansen TF.
(2020, December). Cancers, 12(12). Pages 3728. doi: 10.3390/cancers12123728. PMID: 33322500
11. Age-stratified reference intervals unlock the clinical potential of circulating cell-free DNA as a biomarker of poor outcome for healthy individuals and patients with colorectal cancer
Ørntoft MW, Jensen SØ, Øgaard N, Henriksen TV, Ferm L, Christensen IJ, Reinert T, Larsen OH, Nielsen HJ, Andersen CL. I
(2020, December). International Journal of Cancer, 148(7). Pages 1665-1675. doi: 10.1002/ijc.33434. PMID: 33320961
10. Circulating tumor DNA as a marker of minimal residual disease following local treatment of metastases from colorectal cancer
Boysen AK, Pallisgaard N, Andersen CSA, Spindler KG.
(2020, August). Acta Oncologia, 59(12). Pages 1424-1429. doi: 10.1080/0284186X.2020.1806357. PMID: 32790489
9. Enhanced Performance of DNA Methylation Markers by Simultaneous Measurement of Sense and Antisense DNA Strands after Cytosine Conversion
Sarah Ø Jensen, Nadia Øgaard, Hans Jørgen Nielsen, Jesper B Bramsen, Claus L Andersen
(2020, July). Clinical Chemistry, 66(7). Pages 925-933. doi: 10.1093/clinchem/hvaa100. PMID: 32460325
8. The effect of surgical trauma on circulating free DNA levels in cancer patients - implications for studies of circulating tumor DNA
Henriksen TV, Reinert T, Christensen E, Sethi H, Birkenkamp-Demtröder K, Gögenur M, Gögenur I, Zimmermann BG; IMPROVE Study Group, Dyrskjøt L, Andersen CL.
(2020, May). Molecular Oncology, 14(8). Pages 1670-1679. doi: 10.1002/1878-0261.12729. PMID: 32471011
7. Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients - initial observations
Nygård L, Ahlborn LB, Persson GF, Chandrananda D, Langer JW, Fischer BM, Langer SW, Gabrielaite M, Kjær A, Rosenfeld N, Mouliere F, Østrup O, Vogelius IR, Bentzen SM.
(2020, April). PLoS One, 15(4). doi: 10.1371/journal.pone.0231884. PMID: 32343749. PMCID: PMC7188247
6. Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy: A Randomized Controlled Trial (SUPER)
Skougaard K, Østrup O, Guldbrandsen K, Sørensen B, Meldgaard P, Saghir Z, Gørtz P, Lonsdale MN, Frank MS, Gerke O, Rychwicka-Kielek BA, Persson G, Land LH, Schytte T, Bodtger U, Skuladottir H, Søgaard J, Nielsen SS, Rasmussen TR, Fischer BM.
(2020, March). Clinical Lung Cancer, 21(2). Pages e61-e64. doi: 10.1016/j.cllc.2019.11.002. PMID: 31839533
5. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients with Stages I to III Colorectal CancerAnalysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients with Stages I to III Colorectal Cancer
Thomas Reinert, Tenna Vesterman Henriksen, Emil Christensen, Shruti Charma, Raheleh Salari, Himanshu Sethi, Michael Knudsen, Iver Nordentoft, Hsin-Ta Wu, Antony S. Tin, Mads Heilskov Rasmussen, Søren Vang, Svetlana Shchegrova, Amanda Frydendahl Boll Johansen, Ramya Srinivasan, Zoe Assaf, Mustafa Balcioglu, Alexander Olson, Scott Dashner, Dina Hafez, Samantha Navarro, Shruti Goel, Matthew Rabinowitz, Paul Billings, Stymir Sigurjonsson, Lars Dyrskjøt, Ryan Swenerton, Alexey Aleshin, Søren Laurberg, Anders Husted Madsen, Anne-Sofie Kannerup, Katrine Stribolt, Søren Palmelund Krag. Lene H. Iversen, Kåre Gotschalck Sunesen, Cheng-Ho Jimmy Lin, Bernhard G. Zimmermann, Claus Lindbjerg Andersen
(2019, August). JAMA Oncology, 5(8). Pages 1124-1131. Doi: 10.1001/jamaoncol.2019.0528. PMID: 31070691
4. Cell-free DNA in newly diagnosed patients with glioblastoma - a clinical prospective feasibility study
Nørøxe DS, Østrup O, Yde CW, Ahlborn LB, Nielsen FC, Michaelsen SR, Larsen VA, Skjøth-Rasmussen J, Brennum J, Hamerlik P, Poulsen HS, Lassen U.
(2019, July). Oncotarget, 10(43). Pages 4397-4406. doi: 10.18632/oncotarget.27030. PMID: 31320993. PMCID: PMC6633897
3. Toward liquid biopsies in cancer treatment: Application of circulating tumor DNA
Barlebo Ahlborn L, Østrup O.
(2019, May). APMIS, 127(5). Pages 329-336. doi: 10.1111/apm.12912. PMID: 30784124
2. IMPROVE-IT2: implementing noninvasive circulating tumor DNA analysis to optimize the operative and postoperative treatment for patients with colorectal cancer - intervention trial 2. Study protocol
Jesper Nors, Tenna Vesterman Henriksen, Kåre Andersson Gotschalck, Therese Juul, Jes Søgaard, Lene Hjerrild Iversen, Claus Lindbjerg Andersen
(2020, March). Acta Oncologica, 59(3). Pages 336-341. Doi: 10.1080/0284186X.2019.1711170. PMID: 31920137
1. Application of cell-free DNA for genomic tumor profiling: A feasibility study
Ahlborn LB, Rohrberg KS, Gabrielaite M, Tuxen IV, Yde CW, Spanggaard I, Santoni-Rugiu E, Nielsen FC, Lassen U, Mau-Sorensen M, Østrup O.
(2019, February). Oncotarget, 10(14). Pages 1388-1398. doi: 10.18632/oncotarget.26642. PMID: 30858924. PMCID: PMC6402712
DO YOU HAVE PUBLICATIONS TO SHARE?
Contact Anne Lærke Lorentzen, Scientific Coordiantor, with your publication. In this way you contribute to the shared list of publications done about ctDNA in Denmark.
CONTACT
E-mail: anne.lorentzen@clin.au.dk
Phone: +45 78 45 53 39
ADDRESS FOR THE SECRETARIAT
Science Center Skejby, MOMA
Brendstrupgårdsvej 21, build. A
8200 Aarhus N
CONTACT
ctDNA@clin.au.dk
+45 78 45 53 39